#China #Shanghai #Ada #Innogen #Efsubaglutide Alfa

Innogen's Groundbreaking Presentation at ADA 2026

On June 5 to 8, 2026, Innogen Pharmaceuticals, a leading biopharmaceutical company based in Shanghai, will unveil significant findings from the Phase IIb ENLIGHT study at the American Diabetes Association (ADA) Scientific Sessions in New Orleans, Louisiana. This presentation is set to focus on the efficacy of Efsubaglutide Alfa, particularly aimed at addressing overweight and obesity issues.

The ENLIGHT Study: Key Highlights

The ENLIGHT study involved a diverse cohort of 200 overweight and obese adults, all without diabetes, and was conducted as a randomized, double-blind, placebo-controlled trial. The primary goal was to assess the effectiveness and safety of Efsubaglutide Alfa, which is a next-generation long-acting GLP-1 receptor agonist. During the trial that spanned 18 weeks, participants were administered doses ranging between 5 mg and 20 mg. The outcomes were promising, with significant weight loss reported across all dosage groups when compared to the placebo.

Exceptional Weight Loss Results

A noteworthy aspect of the study was the absence of a weight loss plateau throughout the treatment. Subjects in the Efsubaglutide Alfa group exhibited consistent weight reduction, achieving an average loss of 10.58% for those on a weekly dosage, and 9.70% for participants on a bi-weekly regimen. The reduction in weight was accompanied by substantial improvements in waist circumference and visceral fat, along with enhanced liver fat metabolism indicators. The data suggest a remarkable increase in the muscle-to-fat ratio, highlighting that the weight lost was primarily fat rather than muscle, emphasizing the treatment's beneficial profile.

Robust Safety Profile

From a safety standpoint, no severe hypoglycemic events were recorded during the study, with any gastrointestinal adverse reactions reported being mostly mild to moderate and transient in nature.

A Perspective from Leadership

Dr. Qinghua Wang, the CEO and founder of Innogen, expressed optimism regarding these clinical trial results, stating, "The data presented at this ADA Annual Meeting is very encouraging. As an innovative long-acting treatment originating from China, Efsubaglutide Alfa combines effective weight loss capabilities with muscle preservation, offering distinct advantages and convenient usage. This collection of high-quality clinical evidence showcases Efsubaglutide Alfa's potential in the obesity treatment landscape and substantiates our commitment to advancing to Phase III trials promptly."

Looking Ahead

Innogen has ambitious plans moving forward, eager to expedite the research process further and aims to launch Efsubaglutide Alfa across international markets. Founded in 2014, Innogen focuses on innovative treatments for metabolic diseases, with a proprietary pipeline covering diverse conditions such as Type 1 diabetes, obesity, and more. Efsubaglutide Alfa already holds approvals for use in type 2 diabetes across mainland China and Macau, and its inclusion in China's National Reimbursement Drug List marks a significant milestone for the company.

Conclusion

With the upcoming presentation at the ADA Scientific Sessions, the medical community and stakeholders will be keenly watching how Efsubaglutide Alfa can change the landscape of obesity management. The extensive research and results could pave the way for a new frontier in obesity treatment, ideally benefiting countless individuals both domestically and globally.